<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397707</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-338-1126</org_study_id>
    <secondary_id>2015-000342-30</secondary_id>
    <nct_id>NCT02397707</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of GS-9857 in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</brief_title>
  <official_title>A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose
      of GS-9857 in adults with normal and impaired hepatic function. Adults in the healthy control
      group will be matched to adults with impaired hepatic function by gender, age (± 10 years),
      and body mass index (± 15%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from time zero to the last quantifiable concentration (AUClast) for GS-9857</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinite time (AUCinf) for GS-9857</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GS-9857</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of GS-9857 as measured by incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>Up to 45 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-9857 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-9857 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9857</intervention_name>
    <description>GS-9857 100 mg tablet administered orally</description>
    <arm_group_label>Moderate Hepatic Impaired</arm_group_label>
    <arm_group_label>Severe Hepatic Impaired</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals:

               -  Screening laboratory values within defined thresholds for group

               -  Use of two effective contraception methods if female of childbearing potential or
                  sexually active male

          -  For individuals with moderate hepatic impairment:

               -  Diagnosis of chronic (&gt; 6 months) hepatic impairment

               -  Score on the Child-Pugh-Turcotte (CPT) scale of 7-9 at screening (Child Pugh
                  Class B).

          -  For individuals with severe hepatic impairment:

               -  Diagnosis of chronic (&gt; 6 months) hepatic impairment

               -  Score on the CPT scale of 10-15 at screening (Child Pugh Class C)

          -  For individuals with normal hepatic function:

               -  Hepatitis C Virus (HCV) antibody and hepatitis B surface antigen negative

        Exclusion Criteria:

          -  All individuals:

               -  Pregnant or nursing female or male with pregnant female partner

               -  HIV infection

               -  History of clinically significant illness or any other medical disorder that may
                  interfere with the individual's treatment, assessment or compliance with the
                  protocol

          -  For individuals with moderate or severe hepatic impairment:

               -  Active HCV infection

               -  Current hepatic encephalopathy

               -  Variceal bleeding in the last 6 months unless banded

               -  Prior placement of a portosystemic shunt

               -  History of hepatorenal or hepatopulmonary syndrome

               -  Spontaneous bacterial peritonitis currently or within the last 6 months

               -  Hospitalization within the last 2 months related to cirrhosis

               -  Confirmed hypotension

               -  Suspicion of hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa Stamm, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

